JeffreyL.JorgensenMDPhD

PubMed

• 1 citations
  Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement.
  Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang
  American Journal of Clinical Pathology. 2024-11-04
• CD133 in T-lymphoblastic leukemia is preferentially expressed in early T-phenotype (ETP) and near ETP subtypes.
  Shuyu E, Karen Amelia Nahmod, Beenu Thakral, Wei Wang, Jeffrey L Jorgensen
  Cytometry. Part B, Clinical Cytometry. 2024-09-05
• 3 citations
  Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
  Jennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, David McCue, Fadi G Haddad
  Leukemia & Lymphoma. 2024-09-01

Journal Articles

• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica

Abstracts/Posters

• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018